Form 4: Emergent BioSolutions Director Trades EBS Stock

Emergent BioSolutions Director Sujata Tyagi Dayal reports transactions involving restricted stock units and stock options, including sales to cover tax obligations.

Summary

• Director Sujata Tyagi Dayal of Emergent BioSolutions Inc. (EBS) has reported several transactions.
• On April 30, 2026, Dayal received an annual grant of 25,344 Restricted Stock Units (RSUs) for board and committee service, with vesting tied to continued board membership.
• Also on April 30, 2026, Dayal was granted 11,296 stock options with an exercise price of $7.99, vesting on the same terms as the RSUs.
• On May 1, 2026, Dayal sold 12,781 shares of common stock at a weighted average price of $8.36, and 980 shares at a weighted average price of $8.94.
• These sales were conducted under a Rule 10b5-1 trading plan to satisfy tax obligations related to RSU vesting.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily details routine insider transactions related to compensation and tax obligations, rather than significant strategic shifts or performance indicators.

Positives

• Director received an annual grant of RSUs and stock options, indicating continued compensation and incentive alignment.
• Sales were executed under a Rule 10b5-1 plan, suggesting pre-planned and potentially less market-impactful transactions.
• The transactions are related to fulfilling tax obligations, a standard financial management activity.

Negatives

• Director sold a significant number of shares (13,761 total) shortly after receiving grants.
• The sales occurred at prices below the exercise price of newly granted options, though this is common for tax-related sales.

Risks

• The vesting of RSUs and stock options is contingent on the reporting person remaining a member of the Company's board of directors.
• Sales under a 10b5-1 plan, while pre-planned, still represent a reduction in direct beneficial ownership by a director.

Future Outlook

The filing does not contain forward-looking statements or guidance. It reports on past transactions.

Management Comments

• The sales were made pursuant to a Rule 10b5-1 trading plan for the purpose of satisfying tax obligations relating to the vesting of RSUs.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported ranges upon request.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for insider transactions. The use of Rule 10b5-1 plans by directors is a common practice to manage personal finances and tax liabilities while adhering to insider trading regulations.

Stakeholder Impact

• Shareholders: The sales by a director may be perceived negatively if not understood as part of a pre-planned tax strategy, though the use of a 10b5-1 plan mitigates concerns about opportunistic trading.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.

Next Steps

• Vesting of RSUs and stock options on the day prior to the one-year anniversary of the grant date, subject to continued board membership.
• Potential future transactions under the Rule 10b5-1 plan if applicable.

Key Dates

Keywords

Form 4, Emergent BioSolutions, EBS, Director, Sujata Tyagi Dayal, Restricted Stock Units, RSUs, Stock Options, Rule 10b5-1, Insider Trading, Beneficial Ownership